Jordan M Cloyd1,2, Sarah Hyman3, Tanya Huwig4, Christina Monsour5, Heena Santry5, Celia Wills6, Allan Tsung5, John F P Bridges5,3,4. 1. Department of Surgery, College of Medicine, The Ohio State Wexner Medical Center, Columbus, OH, USA. jordan.cloyd@osumc.edu. 2. Division of Surgical Oncology, The Ohio State University Wexner Medical Center, 410 W 10th Ave, N-907 Doan Hall, Columbus, OH, 43210, USA. jordan.cloyd@osumc.edu. 3. College of Public Health, The Ohio State Wexner Medical Center, Columbus, OH, USA. 4. Department of Biomedical Informatics, College of Medicine, The Ohio State Wexner Medical Center, Columbus, OH, USA. 5. Department of Surgery, College of Medicine, The Ohio State Wexner Medical Center, Columbus, OH, USA. 6. College of Nursing, The Ohio State Wexner Medical Center, Columbus, OH, USA.
Abstract
PURPOSE: Neoadjuvant therapy (NT) is increasingly being offered to patients with pancreatic ductal adenocarcinoma (PDAC) prior to surgical resection. However, the experience and quality of life (QOL) of patients undergoing NT are poorly understood. METHODS: A systematic review of the Cinahl, Embase, Medline, Pubmed, Scopus, and Web of Science databases was conducted to evaluate the available literature pertaining to the experience and QOL of patient's undergoing NT for PDAC. RESULTS: Among 6041 articles screened, only six met criteria for full-text review including three prospective clinical trials of NT with QOL secondary endpoints. Overall, global QOL during or following NT did not significantly change from baseline. Pain scores seemed to improve during NT while the impact of NT on physical functioning varied across studies. No studies were identified evaluating other aspects of the patient experience. CONCLUSION: Although NT appears to have a minor impact on the QOL of patients with PDAC, this systematic review identified significant evidence gaps in the literature. A protocol of a prospective observational cohort study utilizing a digital smartphone app that aims to evaluate the patient experience and longitudinal QOL of patients with PDAC undergoing NT is presented.
PURPOSE: Neoadjuvant therapy (NT) is increasingly being offered to patients with pancreatic ductal adenocarcinoma (PDAC) prior to surgical resection. However, the experience and quality of life (QOL) of patients undergoing NT are poorly understood. METHODS: A systematic review of the Cinahl, Embase, Medline, Pubmed, Scopus, and Web of Science databases was conducted to evaluate the available literature pertaining to the experience and QOL of patient's undergoing NT for PDAC. RESULTS: Among 6041 articles screened, only six met criteria for full-text review including three prospective clinical trials of NT with QOL secondary endpoints. Overall, global QOL during or following NT did not significantly change from baseline. Pain scores seemed to improve during NT while the impact of NT on physical functioning varied across studies. No studies were identified evaluating other aspects of the patient experience. CONCLUSION: Although NT appears to have a minor impact on the QOL of patients with PDAC, this systematic review identified significant evidence gaps in the literature. A protocol of a prospective observational cohort study utilizing a digital smartphone app that aims to evaluate the patient experience and longitudinal QOL of patients with PDAC undergoing NT is presented.
Authors: Juliane Bingener-Casey; Brent A Bauer; Susanne M Cutshall; Pamela E Skaran; Andrea L Cheville; Jeff A Sloan Journal: Minerva Chir Date: 2019-02 Impact factor: 1.000
Authors: Jordan M Cloyd; Matthew H G Katz; Laura Prakash; Gauri R Varadhachary; Robert A Wolff; Rachna T Shroff; Milind Javle; David Fogelman; Michael Overman; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Bruce D Minsky; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William Ross; Priya Bhosale; Eric P Tamm; Huamin Wang; Anirban Maitra; Michael P Kim; Thomas A Aloia; Jean-Nicholas Vauthey; Jason B Fleming; James L Abbruzzese; Peter W T Pisters; Douglas B Evans; Jeffrey E Lee Journal: J Gastrointest Surg Date: 2016-10-24 Impact factor: 3.452
Authors: Ariella M Altman; Keith Wirth; Schelomo Marmor; Emil Lou; Katherine Chang; Jane Y C Hui; Todd M Tuttle; Eric H Jensen; Jason W Denbo Journal: Ann Surg Oncol Date: 2019-07-16 Impact factor: 5.344
Authors: Jordan M Cloyd; Huamin Wang; Michael E Egger; Ching-Wei D Tzeng; Laura R Prakash; Anirban Maitra; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Michael J Overman; Eugene J Koay; Prajnan Das; Joseph M Herman; Michael P Kim; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz Journal: JAMA Surg Date: 2017-11-01 Impact factor: 14.766
Authors: Pablo E Serrano; Joseph M Herman; Kent A Griffith; Mark M Zalupski; Edward J Kim; Tanios S Bekaii-Saab; Edgar Ben-Josef; Laura A Dawson; Jolie Ringash; Alice C Wei Journal: Int J Radiat Oncol Biol Phys Date: 2014-08-04 Impact factor: 7.038
Authors: Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; James S Tomlinson; Andrew K Stewart; David P Winchester; Mark S Talamonti Journal: Cancer Date: 2007-09-15 Impact factor: 6.860
Authors: Ching-Wei D Tzeng; Hop S Tran Cao; Jeffrey E Lee; Peter W T Pisters; Gauri R Varadhachary; Robert A Wolff; James L Abbruzzese; Christopher H Crane; Douglas B Evans; Huamin Wang; Daniel E Abbott; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Matthew H G Katz Journal: J Gastrointest Surg Date: 2013-11-16 Impact factor: 3.452
Authors: Lena Stevens; Zachary J Brown; Ryan Zeh; Christina Monsour; Sharla Wells-Di Gregorio; Heena Santry; Aslam M Ejaz; Timothy Michael Pawlik; Jordan M Cloyd Journal: World J Gastrointest Oncol Date: 2022-06-15
Authors: Lena Schreiber; Ryan Zeh; Christina Monsour; Aslam Ejaz; Allan Tsung; Timothy M Pawlik; Eric Miller; Anne Noonan; Somashekar G Krishna; Heena Santry; Jordan M Cloyd Journal: HPB (Oxford) Date: 2021-10-25 Impact factor: 3.842